Temferon
Newly Diagnosed Unmethylated Glioblastoma Multiforme (GBM)
Key Facts
About Genenta Science
Genenta Science is developing a disruptive immuno-gene therapy platform that engineers a patient's own hematopoietic stem cells to produce therapeutic proteins, like interferon-alpha, directly within the tumor microenvironment. This approach aims to overcome the limitations of systemic drug delivery by creating a sustained, localized anti-tumor effect with potentially reduced toxicity. The company's lead program, Temferon, is in Phase 1/2 clinical trials for glioblastoma multiforme, a highly aggressive brain cancer with limited treatment options. Genenta's strategy focuses on validating its platform in high-unmet-need oncology indications, with the potential to expand into other solid tumors and therapeutic areas.
View full company profileAbout Genenta Science
Genenta Science is developing a disruptive immuno-gene therapy platform that engineers a patient's own hematopoietic stem cells to produce therapeutic proteins, like interferon-alpha, directly within the tumor microenvironment. This approach aims to overcome the limitations of systemic drug delivery by creating a sustained, localized anti-tumor effect with potentially reduced toxicity. The company's lead program, Temferon, is in Phase 1/2 clinical trials for glioblastoma multiforme, a highly aggressive brain cancer with limited treatment options. Genenta's strategy focuses on validating its platform in high-unmet-need oncology indications, with the potential to expand into other solid tumors and therapeutic areas.
View full company profile